Document is current

Article History

Received: 10 May 2021

Revised: 3 February 2022

Accepted: 7 February 2022

First Online: 22 February 2022

Competing interests

: ÁGZ has received institutional grant from Pfizer; has participated in advisory board activities with Novartis, Palex, Pfizer and Astra Zeneca; has received travel grand from Roche, Pfizer and Novartis. MR has received honoraria from Novartis, Roche and Pfizer. MM has received honoraria from Roche/Genentech, Lilly, Pfizer, Novartis and Pierre-Fabre; has participated in consulting or advisory board activities with Roche/Genentech, Novartis, Pfizer, Lilly, Astra Zeneca and Taiho Pharmaceutical; has received speakers’ bureau from Lilly/ImClone, Roche/Genentech and Pierre Fabre; has contracted research fees from Roche, Novartis, and PUMA. All remaining authors have declared no conflicts of interest. Industry was not involved in the study hypothesis/design, execution, analysis, or interpretation.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committees, and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The present study was approved by the Clinical Research Ethics Committees of the following institutions: Fundación Instituto Valenciano de Oncología; Hospital Universitario Virgen del Rocío de Sevilla; Hospital Universitario Puerta del Mar; Hospital Clínico San Carlos de Madrid; Hospital Clinic de Barcelona; Hospital Clínico Universitario de Valencia; Fundación Hospital Alcorcón; Complejo Hospitalario de Toledo; Hospital Mutua de Terrassa; Hospital Universitari de Bellvitge; Hospital General Universitario de Alicante; Hospital Virgen de los Lirios de Alcoy; Hospital Universitari de Girona Dr. Josep Trueta; Hospital Mutua de Terrassa; Hospital Universitari Arnau de Vilanova de Lleida; Fundacio d. Osona per a la Recerca i Educacio Sanitaries – FORES, and by the Regional Institutional Review Boards of Burgos and Soria, Aragon-CEICA, Galicia, Cantabria and Jaen. All participants signed an informed consent and patient information was anonymized and de-identified prior to analysis.